

Adult CIRB - Late Phase Emphasis Meeting Agenda

February 2, 2023

I New Study - Initial Review

EA4211, Randomized Phase III Trial of Chemotherapy vs. Pembrolizumab Plus Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma (Version Date 01/05/23)

II New Study - Initial Review

CCTG-NE1, NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET (Version Date 12/16/22)

III Continuing Review

A011401, Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (Version Date 04/20/22)

IV Continuing Review

NRG-GY026, A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (Version Date 12/06/22)

V Continuing Review

NRG-HN005, A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer (Version Date 02/16/21)



FOR THE NATIONAL CANCER INSTITUTE

VI Continuing Review

S1931, Phase III Trial Of Immunotherapy-Based Combination Therapy With Or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (Probe Trial) (Version Date 04/11/22)

VII Continuing Review

EA2182, A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) (Version Date 01/27/21)
